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Abstract: BACKGROUND Prognosis of Takotsubo syndrome (TTS) remains controversial due to scarcity
of available data. Additionally, the effect of the triggering factors remains elusive. OBJECTIVES This
study compared prognosis between TTS and acute coronary syndrome (ACS) patients and investigated
short- and long-term outcomes in TTS based on different triggers. METHODS Patients with TTS were
enrolled from the International Takotsubo Registry. Long-term mortality of patients with TTS was
compared to an age- and sex-matched cohort of patients with ACS. In addition, short- and long-term
outcomes were compared between different groups according to triggering conditions. RESULTS Overall,
TTS patients had a comparable long-term mortality risk with ACS patients. Of 1,613 TTS patients,
an emotional trigger was detected in 485 patients (30%). Of 630 patients (39%) related to physical
triggers, 98 patients (6%) had acute neurologic disorders, while in the other 532 patients (33%), physical
activities, medical conditions, or procedures were the triggering conditions. The remaining 498 patients
(31%) had no identifiable trigger. TTS patients related to physical stress showed higher mortality rates
than ACS patients during long-term follow-up, whereas patients related to emotional stress had better
outcomes compared with ACS patients. CONCLUSIONS Overall, TTS patients had long-term outcomes
comparable to age- and sex-matched ACS patients. Also, we demonstrated that TTS can either be benign
or a life-threating condition depending on the inciting stress factor. We propose a new classification
based on triggers, which can serve as a clinical tool to predict short- and long-term outcomes of TTS.
(International Takotsubo Registry [InterTAK Registry]; NCT01947621).
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ABSTRACT
BACKGROUND Prognosis of Takotsubo syndrome (TTS) remains controversial due to scarcity of available data.
Additionally, the effect of the triggering factors remains elusive.
OBJECTIVES This study compared prognosis between TTS and acute coronary syndrome (ACS) patients and investi-
gated short- and long-term outcomes in TTS based on different triggers.
METHODS Patients with TTS were enrolled from the International Takotsubo Registry. Long-term mortality of patients
with TTS was compared to an age- and sex-matched cohort of patients with ACS. In addition, short- and long-term
outcomes were compared between different groups according to triggering conditions.
RESULTS Overall, TTS patients had a comparable long-term mortality risk with ACS patients. Of 1,613 TTS patients, an
emotional trigger was detected in 485 patients (30%). Of 630 patients (39%) related to physical triggers, 98 patients
(6%) had acute neurologic disorders, while in the other 532 patients (33%), physical activities, medical conditions, or
procedures were the triggering conditions. The remaining 498 patients (31%) had no identifiable trigger. TTS patients
related to physical stress showed higher mortality rates than ACS patients during long-term follow-up, whereas patients
related to emotional stress had better outcomes compared with ACS patients.
CONCLUSIONS Overall, TTS patients had long-term outcomes comparable to age- and sex-matched ACS patients.
Also, we demonstrated that TTS can either be benign or a life-threating condition depending on the inciting
stress factor. We propose a new classification based on triggers, which can serve as a clinical tool to predict
short- and long-term outcomes of TTS. (International Takotsubo Registry [InterTAK Registry]; NCT01947621)
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T
akotsubo syndrome (TTS) has been consid-
ered a relatively benign condition since its
initial description in 1990 (1). Recently, we
have revealed TTS as a life-threatening condition
with comparable in-hospital adverse outcomes to
acute coronary syndrome (ACS) (2). However, scarce
data exist on long-term outcomes in patients with
TTS compared with patients with ACS.
TTS can be associated with a preceding
emotional or physical stressor, and approxi-
mately two-thirds of patients have identifi-
able triggering events (2,3). Recent data have
indicated that in-hospital outcomes in TTS
patients with a preceding medical illness
are worse than that of patients with an
emotional stressor or without an identified
AB BR E V I A T I O N S
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stressor (4–6). However, the effect of triggering
events on short- and long-term outcome has not been
fully investigated. This is of particular interest, as
triggering factors may significantly affect the prog-
nosis of TTS. Physical stressors include a wide spec-
trum of conditions, such as neurologic conditions,
pheochromocytoma, and other physical activities,
medical conditions, or procedures (7,8), validating
the hypothesis that patients with different physical
triggers have different outcomes.
The aim of the present study was to compare the
prognosis between TTS and ACS patients and to
investigate short- and long-term outcomes in TTS
according to different triggers using the database
from InterTAK (International Takotsubo) Registry
cohort (2,9).
METHODS
PATIENTS AND INCLUSION CRITERIA. TTS patients
were included from the InterTAK Registry as previ-
ously described (2,10). Data were queried from the
University Hospital Zurich and 25 collaborating hos-
pitals in 9 countries (Austria, Finland, France, Ger-
many, Italy, Poland, Switzerland, United Kingdom,
and the United States) from January 1, 2011, to
December 31, 2014. TTS was defined based on modi-
fied Mayo Clinic Diagnostic Criteria (2,11): 1) a tran-
sient wall motion abnormality in the left ventricle
beyond a single epicardial coronary artery distribu-
tion; 2) the absence of obstructive coronary artery
disease or angiographic evidence of acute plaque
rupture, which can explain the wall motion abnor-
mality; 3) new electrocardiographic abnormalities or
elevation in cardiac troponin values; and 4) the
absence of myocarditis. Patients with focal TTS
matching all other criteria, in whom the wall-motion
abnormality was identical to a single coronary artery
territory coincidentally, were included. TTS patients
who died during the acute phase before complete
recovery of wall motion were not excluded. When
eligibility for inclusion was unclear, cases were
reviewed by core members at the University Hospital
Zurich to reach an agreement. As a control group, an
age- and sex-matched cohort of patients with ACS,
including patients with ST-segment elevation
myocardial infarction, non–ST-segment elevation
myocardial infarction, or unstable angina, was
selected from the Zurich Acute Coronary Syndrome
Registry. The detailed methods of ACS patient selec-
tion have already been described in our previous
paper (2). Data on clinical profile and outcome were
collected. This included demographics, vital signs,
cardiovascular risk factors, comorbidities, laboratory
values, results on electrocardiography and coronary
angiography, use of medications, and use of critical
care. Follow-up information of both TTS and ACS
patients was obtained through telephone interviews,
clinical visits, or medical records.
Patients were categorized into respective groups
according to the types of preceding stressors—
emotional stress, physical stress, and no identifiable
trigger. In addition, physical stressors were catego-
rized into 2 groups: 1) physical activities, medical
conditions, or procedures; and 2) neurologic disor-
ders. Patients with the combination of emotional and
physical stress were excluded from the present
analysis.
OUTCOMES. Long-term mortality of patients with
TTS was compared with an age- and sex-matched
cohort of patients with ACS. Additionally, short- and
long-term outcomes including death from any cause
were compared between the TTS groups based on
triggers and with ACS patients.
STATISTICAL ANALYSIS. Continuous data are shown
as mean  SD, skewed variables are presented as
median (interquartile range), and categorical
variables are given as numbers and percentages.
Comparisons of patients’ characteristics between
different groups were performed with 1-way analysis
of variance or the Kruskal-Wallis test for continuous
data and the Pearson chi-square test for categorical
variables.
Outcome analysis was performed using Kaplan-
Meier estimates and log-rank tests, as well as a
landmark analysis with a landmark set at 30 days. Cox
regression analysis was conducted to determine the
hazard ratio (HR) and 95% confidence intervals (CIs)
for long-term outcome of respective trigger factors
using patients with an emotional stressor as a refer-
ence. To account for possible differences in clinical
characteristics and comorbidities between different
TTS groups, a multivariable adjustment analysis,
including covariates that had a significant difference
in the baseline comparison or were likely to have a
relationship to long-term mortality, was performed in
a Cox regression model. Missing data on covariates
were completed with multiple imputations prior to
multivariable Cox regression. An additional Cox
regression analysis to obtain predictors of 30-day
mortality was also performed. All tests were 2-sided,
and statistical significance was defined as p < 0.05.
Statistical analyses were performed using IBM SPSS
Statistics, version 25.0 (IBM, Armonk, New York).
SEE PAGE 883
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Graphs were compiled with Prism 7 (GraphPad, La
Jolla, California).
RESULTS
COMPARISON OF TTS PATIENTS TO AGE- AND
SEX-MATCHED ACS PATIENTS. Of all TTS patients in
the InterTAK Registry, 455 patients were included in
an analysis for the comparison to an age- and sex-
matched cohort of 455 ACS patients, including 233
with ST-segment elevation ACS and 222 with non–ST-
segment elevation ACS (2). Patients’ characteristics
and in-hospital outcomes of the TTS and age- and
sex-matched cohort of ACS have already been pub-
lished elsewhere (2). Long-term mortality analysis
revealed similar outcomes between TTS and ACS
patients (p ¼ 0.49) (Figure 1).
COMPARISON BETWEEN DIFFERENT TRIGGER
GROUPS. To investigate the effects of preceding
stress factors, 1,613 patients were included after the
exclusion of patients whose triggering conditions
could not be clearly differentiated (overlapping of
emotional and physical triggers, n ¼ 137), and cate-
gorized into respective groups based on triggers. A
definite emotional stressor was detected in 485 pa-
tients (30%). Of 630 patients (39%) with a physical
trigger, 98 patients (6%) were identified as having an
acute neurologic disorder. The remaining patients
with a physical trigger (n ¼ 532, 33%) experienced TTS
secondary to physical activities, medical conditions,
or procedures. A total of 31% of TTS patients had no
identifiable triggering factor (n ¼ 498).
Main patient characteristics of all different groups
are summarized in Table 1. The prevalence of women
was significantly higher in TTS related to emotional
stress (95%) versus physical activities, medical con-
ditions, or procedures (85%), TTS secondary to
neurologic disorders (87%), and TTS without an
identifiable triggering factor (91%) (p < 0.001).
Patients with TTS secondary to neurologic diseases
were significantly younger (age 61.8  14.9 years)
compared with the other groups (p < 0.001). Labora-
tory analysis on admission demonstrated that
troponin, creatine kinase, and brain natriuretic pep-
tide were comparable amongst all groups. Inflamma-
tory markers, including C-reactive protein and white
blood cell count, were significantly higher in TTS
secondary to physical activities, medical conditions,
or procedures and TTS secondary to neurologic dis-
eases. There was no difference in electrocardio-
graphic findings on admission. Patients with TTS
secondary to physical activities, medical conditions,
or procedures and TTS secondary to neurologic dis-
eases had higher heart rates and lower left ventricular
ejection fraction on admission (p < 0.001 in both
comparisons). Diabetes mellitus was more common in
TTS secondary to physical activities, medical condi-
tions, or procedures, while less common in TTS sec-
ondary to neurologic diseases. Cancer was more
common in TTS secondary to physical activities,
medical conditions, or procedures and TTS secondary
to neurologic diseases. There were no significant
differences in medications on admission, including
angiotensin-converting enzyme inhibitors or angio-
tensin receptor blockers, beta-blockers, statins, and
aspirin. Acute cardiac care treatment was much more
common in TTS secondary to physical activities,
medical conditions, or procedures (38%) and TTS
secondary to neurologic diseases (50%) compared
with the other groups (p < 0.001) (Table 1).
SHORT- AND LONG-TERM MORTALITY. Comparison
of 30-day mortality between the different groups
based on the triggering conditions demonstrated a
substantial difference (p < 0.001) (Figure 2). Patients
with TTS secondary to neurologic diseases had the
worst prognosis, while patients with TTS related to
emotional stress showed the most favorable outcome.
In addition, a landmark analysis (time point set at
30 days) demonstrated a substantial difference in
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Kaplan-Meier curve for long-term mortality of patients with Takotsubo syndrome
compared with an age- and sex-matched cohort of patients with acute coronary syn-
drome (ACS) including ST-segment elevation (STE) ACS (n ¼ 233) and non–ST-segment
elevation (NSTE) ACS (n ¼ 222). Patients with Takotsubo syndrome had comparable
long-term mortality risk with those with ACS (p ¼ 0.49) or with STE- and NSTE-ACS
(p ¼ 0.79).
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(n ¼ 498) p Value
Demographics
Female 459/485 (94.6) 454/532 (85.3) 85/98 (86.7) 452/498 (90.8) <0.001
Age, yrs 65.4  12.4 (n ¼ 485) 66.5  13.4 (n ¼ 532) 61.8  14.9 (n ¼ 98) 68.0  12.5 (n ¼ 498) <0.001
Takotsubo type
Apical type 384/485 (79.2) 434/532 (81.6) 75/98 (76.5) 426/498 (85.5) 0.033
Cardiac biomarkers on admission



























Inflammatory markers on admission



















Sinus rhythm 427/455 (93.8) 423/470 (90.0) 72/78 (92.3) 417/453 (92.1) 0.20
ST-segment elevation 204/455 (44.8) 181/470 (38.5) 34/77 (44.2) 214/450 (47.6) 0.44
ST-segment depression 27/455 (5.9) 42/470 (8.9) 7/77 (9.1) 31/450 (6.9) 0.31
T-wave inversion 185/455 (40.7) 199/470 (42.3) 25/77 (32.5) 184/450 (40.9) 0.44






































Hypertension 293/478 (61.3) 348/518 (67.2) 54/91 (59.3) 327/477 (68.6) 0.049
Diabetes mellitus 50/476 (10.5) 99/519 (19.1) 6/91 (6.6) 64/481 (13.3) <0.001
Current smoking 85/471 (18.0) 107/505 (21.2) 24/91 (26.4) 79/459 (17.2) 0.15
Hypercholesterolemia 154/478 (32.2) 159/516 (30.8) 27/90 (30.0) 165/478 (34.5) 0.61
Comorbidities
Cancer 48/453 (10.6) 108/497 (21.7) 20/88 (22.7) 65/441 (14.7) <0.001
Psychiatric disorders§ 150/396 (37.9) 162/496 (32.7) 32/90 (35.6) 84/413 (20.3) <0.001
Medication on admission
ACE inhibitor or ARB 158/415 (38.1) 148/422 (35.1) 27/73 (37.0) 154/375 (41.1) 0.38
Beta-blocker 143/415 (34.5) 128/422 (30.3) 20/73 (27.4) 133/375 (35.5) 0.28
Statin 73/403 (18.1) 79/417 (18.9) 11/73 (15.1) 62/362 (17.1) 0.83
Aspirin 141/403 (35.0) 122/417 (29.3) 21/73 (28.8) 132/362 (36.5) 0.17
In-hospital complications 20/479 (4.2) 111/524 (21.2) 23/98 (23.5) 40/483 (8.3) <0.001
Cardiogenic shock 17/479 (3.5) 94/523 (18.0) 13/98 (13.3) 36/483 (7.5) <0.001
Death 5/485 (1.0) 37/532 (7.0) 13/98 (13.3) 14/498 (2.8) <0.001
Acute cardiac care treatment 38/484 (7.9) 199/527 (37.8) 49/98 (50.0) 47/489 (9.6) <0.001
Intra-aortic balloon pump 7/484 (1.4) 21/527 (4.0) 2/98 (2.0) 11/489 (2.2) 0.07
Invasive or noninvasive ventilation 21/484 (4.3) 174/527 (33.0) 45/98 (45.9) 39/489 (8.0) <0.001
Cardiopulmonary resuscitation 16/484 (3.3) 73/527 (13.9) 16/98 (16.3) 33/489 (6.7) <0.001
Catecholamine use 24/484 (5.0) 116/527 (22.0) 28/98 (28.6) 31/489 (6.3) <0.001
Values are n/N (%) mean  SD, or median (interquartile range). *Including upper limits of the normal range for troponin T, high-sensitivity troponin T, and troponin I. †Including upper limits of the normal
range for brain natriuretic peptide and the N-terminal of prohormone brain natriuretic peptide. ‡Data obtained during catheterization or echocardiography; if both results were available, data from cath-
eterization were used. §Patients could have an acute disorder as well as past or chronic disorder.
ACE ¼ angiotensin-converting enzyme; ARB ¼ angiotensin-receptor blocker; BNP ¼ brain natriuretic peptide; CRP ¼ C-reactive protein; ECG ¼ electrocardiogram; QTc ¼ QT interval corrected for heart
rate; ULN ¼ upper limit of the normal; WBC ¼ white blood cell count.
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long-term mortality between the different groups
(p < 0.001) (Figure 2). Whereas patients with TTS
secondary to neurologic diseases and TTS secondary to
physical activities, medical conditions, or procedures
had a less favorable long-term outcome than ACS, pa-
tients with TTS related to emotional stress had
more favorable prognosis compared with ACS.
Preceding physical activities, medical conditions, or
procedures (HR: 3.78; 95% CI: 2.21 to 6.44; p < 0.001),
neurologic disorders (HR: 5.76; 95% CI: 2.96 to 11.2; p<
0.001), and no identifiable trigger (HR: 2.14;
95% CI: 1.20 to 3.82; p ¼ 0.010) emerged as strong in-
dependent risk factors for 5-year mortality when using
preceding emotional stressors as the reference group
(Figure 3). In an additional Cox regression analysis,
preceding physical activities, medical conditions, or
procedures; neurologic disorders; and no identifiable
trigger were also identified as independent
predictors of 30-day mortality (Online Figure 1).
DISCUSSION
The principal findings of the present study were
as follows: 1) overall, TTS patients had a similar
long-term outcome compared with age- and sex-
matched ACS patients; 2) TTS patients with events
related to emotional stress had a favorable short- and
long-term prognosis; 3) TTS secondary to neurologic
diseases had the worst short-term prognosis; and 4)
TTS secondary to neurologic diseases and TTS sec-
ondary to physical activities, medical conditions, or
procedures had significantly higher mortality rates
compared with ACS during long-term follow-up.
Recently, we have reported that in-hospital mor-
tality of TTS is similar to that of ACS (2). However,
scarce data exist on long-term outcomes in patients
with TTS compared with patients with myocardial
infarction (12–14). Additionally, these studies (13,15)
are limited by the fact that they only include pa-
tients with ST-segment elevation myocardial infarc-
tion or non–ST-segment elevation myocardial
infarction as a comparison group without considering
patients with unstable angina, which is important as
TTS patients can also present with signs and symp-
toms of unstable angina and without any notable
electrocardiographic abnormalities. Second, these
studies have had inconsistent results regarding pa-
tient outcomes, with some showing equal mortality
rate to ACS, and some showing increased mortality in
patients with TTS (12,13,15).
TTS is typically triggered by a preceding emotional
or physical stressor, and approximately two-thirds of
patients have identifiable triggering events
(2,3,16,17). We have recently shown that physical
triggers are an independent predictor of a worse
in-hospital outcome (2). However, triggering condi-
tions, especially physical triggers of TTS, vary
substantially, ranging from critical conditions such as
a septic shock treated in the intensive care unit to
harmless conditions including vigorous housework
(7,18). Therefore, we hypothesized that patients with
different physical triggers have different short- and
long-term outcomes.
Of note, TTS patients with an emotional stressor
more often had typical features of TTS, such as female
sex and chest pain, compared with patients in other
groups. Interestingly, patients with TTS secondary to
a neurologic disorder were significantly younger than
TTS patients of other groups. These epidemiological
differences might reflect the biological background.
Patients with TTS secondary to physical activities,
medical conditions, or procedures and those with TTS
secondary to neurologic disorders showed higher
























485 353 253 191 147 108 73
532 361 214 148 111 74 48
98 67 34 23 19 13 7
498 327 249 193 148 108 70
455 377 275 230 174 143 113
Emotional Stress (Class I)
Physical Activities, Medical Conditions, or Procedures (Class IIa)
Neurologic Disorders (Class IIb)
No Stress Factor (Class III)
Acute Coronary Syndrome
Kaplan-Meier survival curve of different triggering groups and acute coronary syndrome
as a reference group with landmark analysis at 30 days. Comparison of 30-day mortality
between the different groups based on the triggering conditions demonstrated a sub-
stantial difference (p < 0.001). After 30 days, a substantial difference in long-term
mortality (5 years) between the different groups still exists (p < 0.001). Patients with
acute coronary syndrome showed intermediate short- and long-term mortality between
patients with emotional and physical TTS triggering groups. TTS ¼ Takotsubo syndrome.
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heart rates compared with those with emotional trig-
gers. This observation might suggest that the degree
of catecholamine surge was more severe in patients
with physical or neurologic triggers than in those with
emotional triggers. Furthermore, it is likely that
higher catecholamine levels can increase the risk of
developing cardiogenic shock via pump failure due to
large ballooning area and/or left ventricular outflow
tract obstruction due to hypercontractility of the basal
segment (19). In addition, inflammatory markers such
as C-reactive protein and white blood cell count were
also higher in patients with physical or neurologic
disorders. Thus, it is conceivable that a synergistic
effect of a severe cardiac dysfunction and enhanced
inflammatory response leads to a poor hemodynamic
status, which in turn causes an unfavorable short-
term outcome.
According to the triggering conditions, TTS pa-
tients with events secondary to neurologic disorders
had the highest mortality; this is also in line with a
recently published work showing that neurologic
diseases are associated with an unfavorable
outcome (10). This is not surprising, as the
prognosis of these patients is likely to be affected
by the underlying disease. In other words, the
increased mortality in patients with neurologic
triggers may be engendered by the combined risk of
TTS plus the intrinsic risk of any precipitating co-
morbidity, such as cerebrovascular hemorrhage.
Patients with TTS secondary to physical activities,
medical conditions, or procedures had the second
worst prognosis at 30-day follow-up. However, TTS
secondary to neurologic disorders and TTS second-
ary to physical activities, medical conditions, or
procedures showed almost similar unfavorable out-
comes at 5 years after the TTS index event; indeed,
neurologic diseases mostly drive patient outcome
during the acute phase. As the mortality rate of TTS
secondary to physical activities, medical conditions,
or procedures increases to that of TTS secondary to
neurologic disease at 5-year follow-up, this may be
explained by a higher prevalence of chronic coex-
isting morbidities such as diabetes mellitus in pa-
tients with TTS secondary to physical activities,
medical conditions, or procedures compared with
those with TTS secondary to neurologic diseases.
FIGURE 3 Outcome Predictors
Emotional stress (Class I)
5-Year Mortality HR (95% CI) p Value
Physical activities, medical conditions, or procedures (Class IIa)
Neurologic disorders (Class IIb)
No stress factor (Class III)
Age >70 yr
Male sex
Systolic blood pressure <130 mm Hg
Heart rate >70 bpm






First troponin >10 x ULN
White blood cell count
3.78 (2.21 - 6.44)
5.76 (2.96 - 11.2)
2.14 (1.20 - 3.82)
1.50 (1.08 - 2.09)
1.75 (1.13 - 2.70)
1.35 (0.96 - 1.89)
1.31 (0.78 - 2.20)
1.86 (1.21 - 2.87)
1.46 (0.89 - 2.38)
1.02 (0.71 - 1.47)
1.42 (0.95 - 2.14)
1.65 (1.14 - 2.40)
1.25 (0.87 - 1.80)
1.29 (0.86 - 1.93)

















Multiple Cox regression to adjust for potential confounders for long-term mortality. Preceding physical activities, medical conditions, or procedures; neurologic
disorders; and no identifiable trigger were identified as strong independent risk factors for 5-year mortality using preceding emotional stressors as the reference group.
In addition, age >70 years, male sex, left ventricular ejection fraction <45%, and cancer emerged as independent predictors. Blue indicates statistically significant
predictors, orange not significant. bpm ¼ beats/min; CI ¼ confidence interval; HR ¼ hazard ratio; ULN ¼ upper limit of the normal range.
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Singh et al. (20) conducted a meta-analysis, which
reported that TTS patients with underlying noncar-
diac conditions showed higher in-hospital mortality
rate compared with those without. Of note, our
study demonstrates different short- and long-term
outcomes of TTS patients with diverse physical
triggers. Additionally, TTS patients with an
emotional stressor showed a favorable short- and
long-term outcome compared with those with a
physical stressor or ACS patients. Therefore, TTS is
a much more complex syndrome than previously
thought, and should be classified according to the
underlying trigger event to accurately risk stratify
and predict short- and long-term outcomes for in-
dividual patients. Thus, we propose a new classifi-
cation according to results of the present study
(Central Illustration). This new classification (Inter-
TAK Classification) could be useful to predict short-
and long-term outcomes of TTS patients.
STUDY LIMITATIONS. This is a registry of an obser-
vational nature. Therefore, invisible confounders
cannot be excluded. Patients with physical activity
were classified as Class IIa and not as a single category
due to the small sample size.
CONCLUSIONS
It was assumed for quite a long time that TTS is a
benign condition; however, it has recently been
shown that TTS is a life-threatening illness with
substantial morbidity and mortality in the acute
phase and outcomes similar to that of ACS. Given the
heterogenous character of triggers, TTS encompasses
a wide spectrum ranging from a benign to fatal con-
dition. As such, TTS is much more multifaceted than
suggested. The old woman with an emotional trig-
gering event and apical ballooning, “the classic TTS
patient,” indeed has a good short- and long-term
prognosis, whereas patients with TTS secondary to
neurologic disorders and TTS secondary to physical
activities, medical conditions, or procedures reveal
an unfavorable outcome. As medicine approaches
delivery of personalized medicine and our knowledge
about TTS grows, it is crucial to consider the “indi-
vidual patient” to perhaps improve prognosis. Thus,
the new InterTAK Classification based on the type of
triggering event might be a useful clinical tool for risk
stratification.
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Takotsubo syndrome related to emotional stress
Takotsubo syndrome related to physical stress
Takotsubo syndrome secondary to physical activities, medical conditions, or procedures
Takotsubo syndrome secondary to neurologic disorders
Takotsubo syndrome without an identifiable triggering factor
Ghadri, J.R. et al. J Am Coll Cardiol. 2018;72(8):874–82.
Novel classification proposed, based on the type of triggering event.
PERSPECTIVES
COMPETENCY IN PATIENT CARE AND PROCEDURAL
SKILLS: The long-term outcome of patients with TTS is highly
variable. The prognosis is more favorable when the syndrome is
triggered by emotional events than when it develops in response
to physical or neurologic conditions.
TRANSLATIONAL OUTLOOK: Further investigation of the
relationships between the triggering provocative circumstances
could help elucidate the pathophysiological mechanisms
responsible for this acute cardiac condition.
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